Diabetes mellitus (DM) is a chronic disease characterized by impaired function of insulin-producing cells of the pancreas. DM is one of the most common endocrine diseases, progressing with age and leading to the impairment of the functions of many tissues and organs of the body. Specialists of the Infinity Clinic have developed comprehensive treatment approaches for DM based on administration of fetal stem cells of the pancreas in combination with hematopoietic fetal stem cells and neural fetal stem cells. Fetal stem cells will migrate into the damaged areas of the pancreas and give rise to new cells that will substitute damaged and dying insulin-producing cells. Also, fetal stem cells will release anti-inflammatory cytokines suppressing chronic inflammation that is recognized as one of the main elements of the pathogenesis of DM. Trophic factors such as insulin-like grows factor-1 that is produced by fetal stem cells could enhance tissue response to the insulin, hence decreasing the amount of necessary daily injections. Additional administration of hematopoietic fetal stem cells and neural fetal stem cells will support engraftment of fetal stem cells of the pancreas, induce regeneration in the tissues of the body and decrease risk of the development of DM-associated complications in neural system. Efficiency of this method was evaluated by the positive dynamics of the level of the glycated hemoglobin and decrease in the total daily dose of the insulin (figures 1, 2).
Figure 1. Results of the treatment of diabetes with fetal stem cells.
The graph illustrates improvement of the level of glycated hemoglobin (HbA1c). Each marker represents mean value calculated from the results acquired from 7 patients ± SD
Figure 2. Results of the treatment of diabetes with fetal stem cells.
The graph illustrates improvement of the level of total daily dose of the insulin. Each marker represents mean value calculated from the results acquired from 7 patients ± SD
ALL STEM CELL PRODUCTS THAT ARE USED FOR THE TREATMENT IN INFINITY CLINIC ARE MANUFACTURED IN OUR RESEARCH AND DEVELOPMENT FACILITY THAT INCLUDES FOLLOWING LABORATORIES:
- Preliminary Anatomical Material Processing Laboratory
- Biotechnological Laboratory
- Biological Safety Control Laboratory
All laboratories equipped according to the GMP* standards
*(Good Manufacturing Practice)
OUR STEM CELL PRODUCTS ARE TESTED IN THE BIOSAFETY LABORATORY FOR THE ABSENCE OF THE FOLLOWING PATHOGENS:
- Aerobic and Anaerobic bacteria
- HBV, HCV, HSV-1/2, HIV-1/2, CMV
- Treponema pallidum
- Mycoplasma hominis
- Chlamydia and Toxoplasma gondii